BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Chronogen Inc. Names Dr. Max Fehlmann, Ph.D. MBA, New President And CEO


10/19/2005 5:12:03 PM

MONTREAL, Nov. 4 /PRNewswire/ -- Chronogen Inc. (http://www.chronogen-inc.com/), a drug discovery company developing human therapeutics to treat age-dependent diseases, announced today the appointment of Max Fehlmann, Ph.D. as its new President and Chief Executive Officer and as a member of its Board of Directors.

Commenting on the appointment, Dr. Yves Fouron, Chairman of the Board of Directors of Chronogen Inc. stated, "We are delighted to have Max join Chronogen as our Chief Executive Officer at this important stage in our evolution. Max brings a wealth of experience relevant to the strategic development of biotechnology businesses. Max's extensive scientific background and operating experience as a senior executive in both private and public Bio- pharmaceutical organizations, will help the company accelerate our product development stage. Prior to this, he was President and CEO of Aster Biotechnologies, which, under his leadership grew from 2 to 35 employees, raised significant private placements and was eventually sold to Zambon Group, a multinational Pharmaceutical Company, who then offered Max the position of R&D director of the entire group". Max holds a Ph.D. from Laval University in Quebec, a DSc from the University of Nice and a MBA from CPA-Mediterrannee in Sophia-Antipolis.

Commenting on his appointment, Dr. Fehlmann said, "I'm very excited about the opportunity which Chronogen represents. With its robust discovery research platform, and its scientific collaborations, the company is well positioned to create value for its drug discovery program targets. My involvement in the biotechnology industry over the last 15 years has given me an appreciation of the combination of great science and effective collaborative business development. I feel that Chronogen has accomplished much in its last year of operation and has the potential to deliver much more. Chronogen is bound to make a number of strategic moves in the near-term".

ABOUT CHRONOGEN

Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of targets that control the degenerative processes of aging. Based on this innovative approach, the company is developing novel products to control lipid and oxidative stress levels, which are established disease mechanisms in cardiovascular disorders. The control of aging in whole model organisms has provided very valuable assets for a drug discovery technology that will lead to novel and efficacious drugs in significant markets including atherosclerosis, vascular complications of diabetes, and ischemia/reperfusion injuries. Chronogen is headquartered in Montreal, Canada. Further information can be found at http://www.chronogen-/ inc.com

CHRONOGEN INC.

CONTACT: Company Contacts: Max Fehlmann, President & CEO,(514) 521-9595, mfehlmann@chronogen-inc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->